Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

European Journal of Cancer

Volumn 49, Issue 7, 2013, Pages 1609-1618

  Harrington, Kevin ^a   Berrier, Alain ^b   Robinson, Martin ^c   Remenar, Eva ^d   Housset, Martin ^e   De Mendoza, Fernando Hurtado ^f   Fayette, Jérôme ^g   Mehanna, Hisham ^h   El Hariry, Iman ⁱ   Compton, Natalie ⁱ   Franklin, Natalie ⁱ   Biswas Baldwin, Nigel ⁱ   Lau, Mike ⁱ   Legenne, Philippe ⁱ   Kumar, Rejnish ^j  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Centre Hospitalier de LENS   (France)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^g UNIVERSITÉ DE LYON   (France)

^h UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j REGIONAL CANCER CENTRE   (India)

more..

Author keywords

Chemoradiotherapy; Chemotherapy; Epidermal growth factor receptor; Head and neck cancer; Human papilloma virus; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; LAPATINIB; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPLETE RESPONSE RATE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; MALE; OVERALL SURVIVAL; PAPILLOMA VIRUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL TIME; TREATMENT DURATION; TUMOR LOCALIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIARRHEA; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRIDAE; QUINAZOLINES; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84876106601     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.023     Document Type: Article

References (11)

1. S.J. Rogers, K.J. Harrington, P. Rhys-Evans, P. O-Charoenrat, and S.A. Eccles Biological significance of c-erbB family oncogenes in head and neck cancer Cancer Metastasis Rev 24 1 2005 47 69 (Pubitemid 40576063)
2. M.E. Sharafinski, R.L. Ferris, S. Ferrone, and J.R. Grandis Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck Head Neck 32 10 2010 1412 1421
3. L.F. Chen, E.E. Cohen, and J.R. Grandis New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors Clin Cancer Res 16 9 2010 2489 2495
4. J. Bourhis, J.L. Lefebvre, and J.B. Vermorken Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options? Eur J Cancer 46 11 2010 1979 1989
5. E.E. Cohen, D.J. Haraf, and R. Kunnavakkam Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer J Clin Oncol 28 20 2010 3336 3343
6. K.J. Harrington, I.A. El-Hariry, and C.S. Holford Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck J Clin Oncol 27 7 2009 1100 1107
7. D. Herchenhorn, F.L. Dias, and C.M. Viegas Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck Int J Radiat Oncol Biol Phys 78 3 2010 696 702
8. K.E. Rusthoven, S.J. Feigenberg, and D. Raben Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer Int J Radiat Oncol Biol Phys 78 4 2010 1020 1025
9. N. Stransky, A.M. Egloff, and A.D. Tward The mutational landscape of head and neck squamous cell carcinoma Science 333 6046 2011 1157 1160
10. C.S. Kong, B. Narasimhan, and H. Cao The relationship between human papilloma virus status and other molecular prognostic markers in head and neck squamous cell carcinomas Int J Radiat Oncol Biol Phys 74 2 2009 553 561
11. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 1 2010 21 28